Navigation Links
Vanda Pharmaceuticals Responds to Announcement and Filing by a Group Led by Tang Capital Partners, LP
Date:2/23/2009

apital necessary to fund its research and development activities; Vanda's failure to identify or obtain rights to new product candidates; Vanda's failure to develop or obtain sales, marketing and distribution resources and expertise or to otherwise manage its growth; a loss of any of Vanda's key scientists or management personnel; losses incurred from product liability claims made against Vanda; a loss of rights to develop and commercialize Vanda's products under its license and sublicense agreements and other factors that are described in the "Risk Factors" section (Part II, Item 1A) of Vanda's quarterly report on Form 10-Q for the quarter ended September 30, 2008 (File No. 000-51863). In addition to the risks described above and in Part II, Item 1A of Vanda's quarterly report on Form 10-Q, other unknown or unpredictable factors also could affect Vanda's results. There can be no assurance that the actual results or developments anticipated by Vanda will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved.

All written and verbal forward-looking statements attributable to Vanda or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. Vanda cautions investors not to rely too heavily on the forward-looking statements Vanda makes or that are made on its behalf. The information in this release is provided only as of the date of this release, and Vanda undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

IMPORTANT INFORMATION/SOLICITATION PARTICIPANTS LEGEND

Vanda Pharmaceuticals and its d
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. FDA Accepts Vanda Pharmaceuticals Iloperidone Resubmission and Sets New Action Date
2. Vanda Pharmaceuticals Announces Receipt of Not Approvable Letter From FDA for Iloperidone
3. Vanda Pharmaceuticals to Present at the FBR Capital Markets 12th Annual Spring Investor Conference
4. Vanda Pharmaceuticals Announces that it No Longer Intends to Offer Convertible Senior Notes
5. Vanda Pharmaceuticals VSF-173 Excessive Sleepiness Phase II Clinical Trial Suggests Wake-Promoting Properties
6. Vanda Pharmaceuticals to Announce Third Quarter 2007 Financial Results on November 8, 2007
7. Vanda Pharmaceuticals to Present New Data on Iloperidone at the 2007 American Society of Human Genetics Annual Meeting
8. Vanda Pharmaceuticals to Present at Natixis Bleichroeders Hidden Gems Conference
9. Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2008 Financial Results
10. Nostrum Pharmaceuticals Obtains Worldwide Licensing Rights From IMTECH for Clinical Development of the Small Molecule Caerulomycin and Its Proprietary Derivatives for Their Novel Indication of Immunosuppression
11. Anadys Pharmaceuticals to Report Fourth Quarter and Year End 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... Greifensee, Switzerland (PRWEB) , ... September 01, 2015 ... ... “Calibration and Qualification of Laboratory Instruments in accordance with GMP requirements“ , ... be presented on October 6th, 2015 at 11:00 EDT (15:00 GMT). , ...
(Date:9/1/2015)... , ... September 01, 2015 , ... Mercy Health (formerly ... devoted the 10th of its monthly Mercy Health: Helping You Be Well videos to ... in seven men. , In a concise video on Mercy Health’s YouTube channel, ...
(Date:9/1/2015)... , ... September 01, 2015 , ... ... 9, 2015 from 5:00 to 8:00 pm at the Marriott Indianapolis Downtown, 350 ... with career opportunities will be attending from across the country. All specialties will ...
(Date:9/1/2015)... ... September 01, 2015 , ... Éminence Organic Skin Care ... VitaSkin™ Exfoliating Peels. This revolutionary collection of natural peel solutions complements the existing ... , Formulated with alpha hydroxy acids and natural active ingredients, these results-oriented ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... has established the MAP Recovery Network, the Premier Outcomes-Driven Provider Network. It ... rapidly-growing alliance is dedicated to the provision of quality addiction treatment and ...
Breaking Medicine News(10 mins):Health News:Live Webinar from Pharmaceutical Technology and METTLER TOLEDO on Calibration and Qualification of Laboratory Instruments 2Health News:New Mercy Health Video Explains Most-Common Cancer Found in Men 2Health News:PracticeMatch to Host Physician Career Fair at the Marriott Indianapolis Downtown on September 9, 2015 2Health News:PracticeMatch to Host Physician Career Fair at the Marriott Indianapolis Downtown on September 9, 2015 3Health News:PracticeMatch to Host Physician Career Fair at the Marriott Indianapolis Downtown on September 9, 2015 4Health News:Éminence Organic Skin Care Introduces Results-Oriented Exfoliating Peels for Every Skin Type 2Health News:Éminence Organic Skin Care Introduces Results-Oriented Exfoliating Peels for Every Skin Type 3Health News:MAP Health Management Launches the MAP Recovery Network 2
... or engineer? Sex hormones strongly influence people,s interests, ... according to psychologists. , "Our results provide strong ... characterized by working with things versus people," said ... with Sheri A. Berenbaum, professor of psychology and ...
... 1 (HealthDay News) -- The intensity of exercise, not the ... of living a longer life, a new study suggests. ... with high levels of cycling intensity lived 5.3 years longer, ... men with low intensity. Among female cyclists, those with ...
... IL A natural yellowing of the eye lens that absorbs ... of test volunteers, according to a,study in the September 1 issue ... discoloration worsened with age, so did the risk of insomnia. ... why sleep disorders become more frequent with increasing age," said Line ...
... hospitalization rates in adolescents and young adults aged 15 ... 2008 according to a study conducted by researchers at ... findings available today in Annals of Neurology , ... Child Neurology Society, report an increase in the prevalence ...
... the September issue of the Journal of the American ... in chest computed tomography (CT) scans. Chest CT is the ... the cause of clinical signs or symptoms of the chest, ... Regardless of the body region being scanned, dose ...
... , WEDNESDAY, Aug. 31 (HealthDay News) -- New research ... files could greatly improve care for diabetic patients by ... faster" at various kinds of medical clinics that had ... Cebul, a professor of medicine at Case Western Reserve ...
Cached Medicine News:Health News:Sex hormones impact career choices 2Health News:Aging eyes linked to sleepless nights, new study shows 2Health News:Increased prevalence of stroke hospitalizations seen in teens and young adults 2Health News:Electronic Medical Records Might Boost Diabetes Care 2Health News:Electronic Medical Records Might Boost Diabetes Care 3
(Date:9/1/2015)... Belgium , Sept. 1, 2015 VolitionRx ... on developing blood-based diagnostic tests for a broad range of ... Executive Officer, Cameron Reynolds , is scheduled to attend ... is being held September 9-10, 2015 in Boston, ... on September 10. Wells Fargo Securities Research ...
(Date:9/1/2015)... , Sept. 1, 2015 Sargas ... Management (CCM) and Drug Adherence m Health applications ... automate the process of non face-to-face monitoring of ... this new release of our apps, doctors are ... services along with our ONCHIT certified Physician, Pharmacy ...
(Date:9/1/2015)... Sept. 1, 2015   Ivenix Inc. , ... management system, closed on a $42M round of ... Ventures. Cardinal Partners, CICA, Inc., Easterly Capital, Fidelity ... the round. This financing will support the company,s ... Leerink Partners LLC acted as the exclusive placement ...
Breaking Medicine Technology:VolitionRx to Attend 10th Annual Wells Fargo Healthcare Conference on September 9-10, 2015 2VolitionRx to Attend 10th Annual Wells Fargo Healthcare Conference on September 9-10, 2015 3VolitionRx to Attend 10th Annual Wells Fargo Healthcare Conference on September 9-10, 2015 4SPAC International's Drug Adherence and Chronic Care Management App Now available at Apple App and Google Play stores 2Ivenix Inc. Secures $42 Million in Funding 2Ivenix Inc. Secures $42 Million in Funding 3
... telangiectasia-like disease and Nijmegen breakage syndrome offer ... and cancer vulnerability in people carrying the ... Scientists at St. Jude Children,s Research Hospital ... two related neurological diseases--ataxia telangiectasia-like disease (ATLD) ...
... MannKind Corporation (Nasdaq: MNKD ) ... equivalence of its commercial inhaler to the version of ... deliver AFRESA(TM), MannKind,s ultra rapid acting insulin that recently ... Bioequivalence of Clinical and Commercial Scale Inhalers Study 138 ...
Cached Medicine Technology:Study Shows How Defective DNA Repair Triggers Two Neurological Diseases 2Study Shows How Defective DNA Repair Triggers Two Neurological Diseases 3MannKind Reports Successful Completion of Device Bioequivalence Trial 2MannKind Reports Successful Completion of Device Bioequivalence Trial 3
... Chamber Lenses: The Bausch & Lomb PMMA Posterior ... for primary implantation for the visual correction of ... older where a cataractous lens has been removed ... to be placed in the ciliary sulcus or ...
... are manufactured using the highest ... CQ UV PMMA material is ... single piece lenses. Unioptic lens ... nonphaco and phaco styles. All ...
... STAARVISC II is a sterile nonpyrogenic, ... hyaluronate. STAARVISC II contains 12 mg/ml of ... daltons) sodium hyaluronate dissolved in physiological saline. ... the viscosity is 105,000 cps (105 Pa ...
... viscoelastic agent for the surgeon who performs ... Amvisc possesses sufficient viscosity for excellent chamber ... cohesive so that complete removal at the ... quickly accomplished. Amvisc is priced to compete ...
Medicine Products: